Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1273.222
- Development stage
- Approved
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1273.222 is a bivalent, lipid nanoparticle-formulated messenger RNA (mRNA) vaccine developed by Moderna for use as a booster against COVID-19[1][2][3]. It encodes the spike protein of both the original SARS-CoV-2 strain and the Omicron BA.4/BA.5 subvariants, aiming to broaden immune protection against circulating variants[1][2][6]. The vaccine works by delivering synthetic mRNA sequences that instruct host cells to produce viral spike proteins, thereby eliciting an immune response characterized by neutralizing antibody production and cellular immunity[1][2]. Clinical trials have demonstrated that mRNA-1273.222 induces superior neutralizing antibody responses against Omicron BA.4/BA.5 compared to earlier monovalent boosters, with a safety profile similar to previous Moderna vaccines[2][3]. Its primary indication is as a booster dose for adults previously vaccinated against COVID-19.
- Brand names
- Spikevax
- Other names
- Moderna BA.4/BA.5 bivalent COVID-19 boosterOmicron BA.4/BA.5 bivalent vaccine
02
Targets
NTD (SARS-CoV-2 spike protein N-terminal domain)RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on mRNA-1273.222.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1273.222.